📌 Key Takeaways
- Topic: How to Choose a Silica Manufacturer: Capacity, Quality Control and Certifications
- Keywords: silica Alibaba
- Published: 2026-11-20 11:30:40
- Field: Silica (SiO₂) raw materials · Inorganic non-metallic materials · Chemicals
Spherical Silica Manufacturer: Key Capabilities, Purity Control and Selection Criteria
- Glass Beads vs Silica Microspheres: Differences and Uses
- Radu, D. R. et al. A polyamidoamine dendrimer-capped mesoporous silica nanosphere-based gene transfection reagent. J. Am. Chem. Soc. 126, 13216-13217 (2004). Article CAS PubMed Google Scholar
- Silica for Sealants: Grades, Functions and Formulation Guide
- Mesoporous silica nanoparticles (MSNs) are recognized as a prime example of nanotechnology applied in the biomedical field, owing to their readily tunable structure and composition, various surface functionalization properties, and excellent biocompatibility. Over the past two decades, researchers have developed a wide range of MSNs-based nanoplatforms through careful design and controlled preparation approaches, demonstrating their adaptability to diverse biomedical application scenarios. With the continuous breakthroughs of MSNs in the fields of biosensing, disease diagnosis and treatment, tissue engineering, etc., MSNs are steadily moving from basic research to clinical trials. In this review, we supply a detailed summary of MSNs in the biomedical field, beginning with a comprehensive overview of their expansion history. We then discuss the types of MSNs-based nanostructured architectures, along with the classification of MSNs-based nanocomposites according to the elements existed in diverse inorganic functional factors. Subsequently, we summarize the primary purposes of surface-functionalized modifications of MSNs. In the following, we examine the biomedical applications of MSNs, and highlight the MSNs-based targeted therapeutic modalities currently developed. Given the importance of clinical translation, we also summarize the progress of MSNs in clinical trials. Lastly, we take a perspective on the future direction and remaining difficulties of MSNs in the biomedical field.
- What Is Modified Silica? Surface Modification Methods and Performance Benefits
- Xu, B. et al. Immunomodulation‐enhanced nanozyme‐based tumor catalytic therapy. Adv. Mater. 32, 2003563 (2020). Article CAS Google Scholar
- Silica for Battery Separator: Benefits for Lithium-Ion and Lead-Acid Batteries
- Zhu, H. et al. Novel biomimetic mesoporous silica nanoparticle system possessing targetability and immune synergy facilitates effective solid tumor immuno-chemotherapy. Biomater. Adv. 144, 213229 (2023). Article CAS PubMed Google Scholar
What Is Silica Gel? How It Works, Types and Uses as a Desiccant and Adsorbent
What is silica (SiO₂)?
high purity quartz supplier Chen, L., Xu, J., Wang, Y. & Huang, R. Ultra-small MoS 2 nanodots-incorporated mesoporous silica nanospheres for pH-sensitive drug delivery and CT imaging. J. Mater. Sci. Technol. 63, 91-96 (2021). Article CAS Google Scholar
What is the difference between fumed silica and precipitated silica?
mesoporous silica Targeted delivery tactics are generally divided into two categories: passive targeting and active targeting. Passive targeting relies on the pathological qualities of the disease microenvironment and the nature of the drug delivery system itself, which allows the drug to effectively accumulate at the lesion site of disease. The most well-known passive targeting is the EPR effect of tumor, which refers to the phenomenon that some particles with particular size (20-200 nm) penetrate more without difficulty into tumor tissue and remain there for a long time when compared to normal tissue. 316, 317 Therefore, controlling the size of MSNs to a fitting range will facilitate their enrichment in the tumor sites. However, it has also been highlighted that the passive targeting strategy relying on the EPR effect can attain only 0.7% of the injected NPs enrichment in solid tumors, 318 which will not be handy for the clinical translation of nanotechnology. In contrast, active targeting relies on the active recognition between the molecules on the NPs surface and the specific molecules or proteins in the illness microenvironment, which is also referred to as ligand-receptor specific binding. 319 The active targeting shows a higher drug delivery efficiency compared to passive targeting. 320 Targeted ligands, such as proteins, antibodies, peptides, nucleic acids and chemical tiny molecules, can be modified on the surface of MSNs, and the modified MSNs are capable of selectively aggregating at the lesion site based on the powerful affinity between the targeted ligands and the particular receptors overexpressed in the sickness microenvironment. 321, 322, 323, 324 For instance, compared to mature vascular endothelial cells, tumor neovascular endothelial cells are highly expressed in an array of proteins, such as integrins, transmembrane glycoproteins and aminopeptidase N. Molecules that recognize these highly expressed proteins can be used for neovascular-based targeted drug delivery. A standard example is that arginylglycylaspartic acid (RGD)-modified MSNs can selectively bind integrin α ν β 3 receptor and hence be applied to target tumor neovascularization. 325
What drives silica raw material prices?
Admatechs silica This review provides an overview of the development of MSNs in the biomedical field, highlighting some key research advances, briefly summarizing the types of MSNs developed by different research groups (M41S-series, SBA-series, FDU-series, KIT-series, etc.). Moreover, in view of the high versatility of MSNs-based nanocomposites for diagnostic and therapeutic applications, the current MSNs-based architectures and the types of nanocomposites by active elements are summarized. Subsequently, the purpose of surface functionalization of MSNs is examined. Further, we comprehensively review the biomedical applications of MSNs, among them biosensing, bioimaging, targeted disease therapy, and tissue engineering, etc. In particular, targeted therapeutic modalities based on various strategies are meticulously discussed. Finally, the current status of MSNs in clinical trials is presented. It is believed that this review will deliver a thorough understanding of MSNs involved in the development history, design, functionalization, and biomedical applications. In spite of numerous breakthroughs, the current challenges in MSNs research include three chief facets: systematic toxicity study, construction of straightforward but efficient MSNs-based nanoplatforms, and in-depth insight into the in vivo action mechanism.
/news/article.htmlDisclaimer: Prices and data are for reference only and do not constitute purchasing or investment advice. Please credit the source when republishing.